Concepedia

Irene Eiseman

IE

13

Publications

616

Citations

11

H-Index

1995

Active since

Affiliations

Pfizer (United States)(Current)

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

Wayne State University

Texas Oncology

Irene Eiseman is an author at Pfizer (United States) specializing in medicine, cancer therapeutics, and oncology.

Top concepts

Publications per year

1995–2007

13

Publications

13

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer

Pasi A. Jänne, Joachim von Pawel, Roger B. Cohen et al. · Journal of Clinical Oncology · 2007 · 118 citations · Full text

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

Lee F. Allen, P Lenehan, Irene Eiseman et al. · Seminars in Oncology · 2002 · 104 citations

, , +7

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

John Nemunaitis, Irene Eiseman, Casey Cunningham et al. · Clinical Cancer Research · 2005 · 86 citations · Full text

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

Emiliano Calvo, Anthony W. Tolcher, Lisa A. Hammond et al. · Clinical Cancer Research · 2004 · 81 citations

Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections

Ghodrat A. Siami, N. V. Christou, Irene Eiseman et al. · Antimicrobial Agents and Chemotherapy · 2001 · 71 citations · Full text

Rows per page

1–5 of 13